Newsfile Corp
14 Jun 2026, 17:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri trial failed to observe a statistically significant reduction in Stage III-IV cancers, which is its primary endpoint. — Failure to meet a primary clinical endpoint for a flagship product is a fundamental negative for a healthcare company's valuation and commercial viability.
-0.90Grail is facing a class action lawsuit alleging that the company made false or misleading statements regarding the probability of success for the NHS-Galleri trial. — Securities litigation creates potential for significant financial settlements and damages company reputation and management credibility.
-0.40Grail's stock price fell by more than 50% following the announcement of the failed trial endpoint on February 19, 2026. — While this is a historical data point, it confirms the market's high sensitivity to the trial's outcome and establishes a baseline of volatility.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is mentioned as the subject of a class action lawsuit for investors with substantial losses.
The company is facing a class action lawsuit alleging securities fraud and the failure of a primary clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
